Amneal Pharmaceuticals (AMRX) Operating Leases (2018 - 2026)

Amneal Pharmaceuticals has reported Operating Leases for 9 years, with the latest figure at $38.7 million in Q2 2026.

• On a quarterly basis, Operating Leases rose 40.07% year-over-year to $38.7 million in Q2 2026; TTM through Jun 2026 was $38.7 million, a 40.07% increase from a year earlier, with the FY2025 full-year figure at $58.8 million, up 25.01% from the prior year.
• Operating Leases was $38.7 million for Q2 2026 at Amneal Pharmaceuticals, down from $41.1 million in the prior quarter.
• The five-year high for Operating Leases was $59.2 million in Q4 2022, with the low at $22.9 million in Q1 2025.
• Average Operating Leases over 5 years is $34.5 million, with a median of $28.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Leases fell 19.03% in 2022, then surged 79.84% in 2026.
• Over 5 years, Operating Leases stood at $59.2 million in 2022, then decreased by 17.42% to $48.9 million in 2023, then declined by 3.84% to $47.0 million in 2024, then rose by 25.01% to $58.8 million in 2025, then plunged by 34.2% to $38.7 million in 2026.
• The last three Operating Leases figures came in at $38.7 million (Q2 2026), $41.1 million (Q1 2026), and $58.8 million (Q4 2025), per Business Quant data.